Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. (Q48589819)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 September 2017

Language	Label	Description	Also known as
English	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.	scientific article published on 12 September 2017

Statements

scholarly article

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

Juliana Chung-ngor Chan

3

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Hertzel C. Gerstein

7

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

object named as

Richard Gray

8

0 references

Jaakko Tuomilehto

18

object named as

Jaakko Tuomilehto

1 reference

Europe PubMed Central

13 February 2018

Michał Tendera

16

object named as

Michal Tendera

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

11

object named as

John J McMurray

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

object named as

Wenying Yang

20

0 references

object named as

Duolao Wang

21

0 references

author name string

Rury R Holman

1

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Ruth L Coleman

2

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Jean-Louis Chiasson

4

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Huimei Feng

5

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Junbo Ge

6

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yong Huo

9

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Zhihui Lang

10

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Lars Rydén

12

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Stefan Schröder

13

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yihong Sun

14

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Michael J Theodorakis

15

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Lynne Tucker

17

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Yidong Wei

19

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Dayi Hu

22

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Changyu Pan

23

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

ACE Study Group

24

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

publication date

12 September 2017

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

5

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

11

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

877-886

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

On the potential of acarbose to reduce cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of nateglinide on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of impaired glucose tolerance in the Pima Indians.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Determining the most appropriate components for a composite clinical trial outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930309-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30309-1

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28917545

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48589819&oldid=1631892579"